Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy ...
IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).
Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...
Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 ...
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active ...
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
Kura Oncology's FDA-approved Komzifti and strong financials offer growth potential in the evolving AML market. Learn more ...
Explore Precision BioSciences' advances in gene therapy for hepatitis B, strong funding till 2028, and what it means for ...
Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations Date: Thursday, December 11, 2025 Time: 5 p.
Zymeworks’ management will participate in one-on-one meetings and a corporate presentation on January 14, 2026, at 3:00 pm PT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback